ITCH (Ab-420) Antibody

Shipped with Ice Packs
In Stock

Description

Antigen and Immunogen

The ITCH (Ab-420) Antibody is synthesized against a phosphorylated peptide derived from human ITCH, specifically around tyrosine 420 (F-I-Y(p)-G-N) . This phosphosite-specific design ensures precise recognition of ITCH in its active state, making it suitable for studying post-translational modifications (PTMs) in cellular pathways .

Production and Validation

  • Source: The antibody is produced in rabbits via peptide immunization, followed by affinity purification to enhance specificity .

  • Cross-reactivity: It exhibits reactivity with human and mouse ITCH proteins, enabling cross-species research applications .

  • Applications: Validated for Western blot (WB) and enzyme-linked immunosorbent assay (ELISA), with recommended dilutions of 1:500–1:3000 (WB) and 1:2000–1:10000 (ELISA) .

AssayRecommended DilutionSpecies
WB1:500–1:3000Human, Mouse
ELISA1:2000–1:10000Human, Mouse

ITCH Protein Function

ITCH (E3 ubiquitin-protein ligase Itchy) belongs to the Nedd4 family of HECT domain ligases, mediating ubiquitination of target proteins for lysosomal degradation . Its roles include:

  • Immune regulation: Promoting T-cell activation and cytokine signaling .

  • Oncogenic regulation: Modulating receptor turnover in cancer cells .

  • Viral interactions: Associating with Epstein-Barr virus LMP2A to suppress B-cell signaling .

Comparison with Other ITCH Antibodies

SourceFormatReactivityApplications
Assay Genie Rabbit IgG (Ab-420)Human, MouseWB, ELISA
Cusabio Recombinant MonoclonalHumanWB, ELISA
Boster Bio Rabbit IgG (A00195)Human, Mouse, RatWB, IHC, ELISA

Research Applications

  • Cancer studies: ITCH antibodies are used to investigate receptor degradation in tumor cells, such as CXCR4 in invasive ductal carcinoma .

  • Autoimmune diseases: ITCH’s role in T-cell regulation makes it a target for therapies in multisystem autoimmune disorders .

  • Neurological research: Detection of ITCH in mouse brain lysates highlights its function in neuronal protein turnover .

Western Blot Validation

Western blot analysis using the ITCH (Ab-420) Antibody demonstrates:

  • Specific binding: Detects a single band at ~102 kDa in HepG2 and mouse brain lysates .

  • Blocking peptide control: Pre-incubation with the immunogen peptide abrogates signal, confirming specificity .

Product Specs

Form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Lead Time
Typically, we can ship your orders within 1-3 business days of receipt. Delivery times may vary depending on the shipping method and destination. Please consult your local distributor for specific delivery information.
Synonyms
ADMFD antibody; AIF4 antibody; AIP4 antibody; Atrophin 1 interacting protein 4 antibody; Atrophin-1-interacting protein 4 antibody; dJ468O1.1 antibody; dJ468O1.1 (atrophin 1 interacting protein 4 (AIP4)) antibody; dJ468O1.1 atrophin 1 interacting protein 4 AIP4 antibody; E3 ubiquitin protein ligase Itchy homolog antibody; E3 ubiquitin-protein ligase Itchy homolog antibody; EC 6.3.2 antibody; Itch antibody; ITCH_HUMAN antibody; Itchy E3 ubiquitin protein ligase antibody; Itchy E3 ubiquitin protein ligase homolog antibody; Itchy E3 ubiquitin protein ligase homolog mouse antibody; Itchy E3 ubiquitin protein ligase, mouse, homolog of antibody; Itchy homolog E3 ubiquitin protein ligase antibody; Itchy mouse homolog E3 ubiquitin protein ligase antibody; NAPP1 antibody; NFE2 associated polypeptide 1 antibody; NFE2-associated polypeptide 1 antibody; Ubiquitin protein ligase ITCH antibody
Target Names
Uniprot No.

Target Background

Function
ITCH (also known as AIP4, RNF144, or Itchy homolog) is an E3 ubiquitin-protein ligase. It accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and directly transfers the ubiquitin to targeted substrates. This enzyme catalyzes 'Lys-29'-, 'Lys-48'- and 'Lys-63'-linked ubiquitin conjugation. ITCH is implicated in the control of inflammatory signaling pathways. It is a key component of a ubiquitin-editing protein complex, along with TNFAIP3, TAX1BP1 and RNF11, which ensures the transient nature of inflammatory signaling pathways. Following TNF stimulation, ITCH promotes the association of this complex. Once formed, TNFAIP3 deubiquitinates 'Lys-63' polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation, and consequently, termination of the TNF- or LPS-mediated activation of NFKB1. ITCH ubiquitinates RIPK2 by 'Lys-63'-linked conjugation and influences NOD2-dependent signal transduction pathways. It regulates the transcriptional activity of several transcription factors, suggesting a significant role in regulating immune response. ITCH ubiquitinates NFE2 by 'Lys-63' linkages, potentially influencing the development of hematopoietic lineages. This enzyme mediates JUN and JUNB ubiquitination and degradation, acting as a critical regulator of type 2 helper T (Th2) cell cytokine production by inducing JUNB ubiquitination and degradation. ITCH is also involved in the negative regulation of MAVS-dependent cellular antiviral responses. It ubiquitinates MAVS through 'Lys-48'-linked conjugation, leading to MAVS proteasomal degradation. Following ligand stimulation, ITCH regulates sorting of Wnt receptor FZD4 to the degradative endocytic pathway, likely by modulating PI42KA activity. ITCH ubiquitinates PI4K2A and negatively regulates its catalytic activity. It also ubiquitinates chemokine receptor CXCR4 and regulates its sorting to the degradative endocytic pathway following ligand stimulation by ubiquitinating endosomal sorting complex required for transport ESCRT-0 components HGS and STAM. ITCH targets DTX1 for lysosomal degradation and controls NOTCH1 degradation, in the absence of ligand, through 'Lys-29'-linked polyubiquitination. ITCH also ubiquitinates SNX9 and MAP3K7 through 'Lys-48'-linked conjugation. This enzyme is involved in the regulation of apoptosis and reactive oxygen species levels through the ubiquitination and proteasomal degradation of TXNIP. ITCH mediates the antiapoptotic activity of epidermal growth factor through the ubiquitination and proteasomal degradation of p15 BID. It also ubiquitinates BRAT1, and this ubiquitination is enhanced in the presence of NDFIP1. ITCH inhibits the replication of influenza A virus (IAV) via ubiquitination of IAV matrix protein 1 (M1) through 'Lys-48'-linked conjugation, leading to M1 proteasomal degradation.
Gene References Into Functions
  1. circ-ITCH was significantly decreased in BCa and correlated with poor prognosis of BCa patients. Moreover, circ-ITCH suppressed cell proliferation, migration and invasion in vitro and tumorigenesis in vivo. PMID: 29386015
  2. The Itch/beta-arrestin2 complex binds SuFu and induces its Lys63-linked polyubiquitylation without affecting its stability. PMID: 29515120
  3. JunB neddylation mediated by Itch promotes its ubiquitination-dependent degradation. PMID: 27245101
  4. An autoinhibitory mechanism for ITCH ubiquitin ligase involves a linker-HECT domain interaction. This intramolecular interaction traps the HECT enzyme in its inactive state and can be relieved by linker phosphorylation. PMID: 28475870
  5. The E3 ubiquitin ligase Itch forms a complex with tricellulin and thereby enhances its ubiquitination. PMID: 28436082
  6. ASPP2 suppresses invasion, peritoneal dissemination and TGF-beta1-induced EMT by inhibiting Smad7 degradation mediated by ITCH in gastric cancer cells. PMID: 28400336
  7. WBP2/ITCH signaling functions to link the intricate Wnt and Hippo signaling networks in breast cancer. PMID: 27578003
  8. The cellular ubiquitin ligase, Itch, is required for Kaposi's sarcoma herpesvirus RTA induced degradation of vFLIP. PMID: 27912080
  9. Itch, ubiquitin, and Alix control the BFRF1-mediated modulation of the nuclear envelope and human herpesvirus 4 maturation, uncovering novel regulatory mechanisms of nuclear egress of viral nucleocapsids. PMID: 27466427
  10. The PPxY L domain motif of ebolavirus VP40 interacts specifically with the WW domain of the host E3 ubiquitin ligase ITCH. PMID: 27489272
  11. Molecular basis of interactions between SH3 domain-containing proteins and the proline-rich region of the ubiquitin ligase Itch. PMID: 28235806
  12. cir-ITCH may play an inhibitory role in lung cancer progression by enhancing its parental gene, ITCH, expression PMID: 27642589
  13. Itch monoubiquitinates SMN and monoubiquitination of SMN plays an important role in regulating its cellular localization. PMID: 26908624
  14. miR-106b, which itself is down regulated in metastatic pancreatic cancer, directly interacts and inhibits ITCH expression. PMID: 26621835
  15. LRAD3 is a component of pathways that function effectively to modulate Itch and Nedd4 auto-ubiquitination and levels. PMID: 26854353
  16. Cytomegalovirus UL42 induced the ubiquitination and degradation of human Itch in virus-infected fibroblasts, and was partially colocalized with p62, a ubiquitin-binding protein, and CD63, a marker of lysosome and multivesicular bodies. PMID: 26555021
  17. catalytic activity of Itch toward different SH3 domain-containing proteins was similar, except for beta-PIX that was not readily ubiquitylated even though it could interact with an affinity comparable to those of other substrates tested PMID: 26613292
  18. Upregulated microRNA-214 enhances cardiac injury by targeting ITCH during coxsackievirus infection. PMID: 25815880
  19. Cell proliferation of hepatocellular carcinoma cells mediated by miR-411, is through suppression of ITCH expression. PMID: 25776495
  20. In the absence of Ndfip1, the Nedd4 family member Itch can bind an E2 but cannot accept ubiquitin onto its catalytic cysteine. PMID: 26245901
  21. These observations indicate that ITCH is involved in the cytosolic quality control pathway and may help to explain how abnormal proteins are targeted by QC ubiquitin-protein ligases. PMID: 24865853
  22. Results suggest that Itch is a positive regulator of the TGF-beta-mediated Smad signaling pathway via Smad7 ubiquitination and protein degradation. PMID: 25518932
  23. ITCH up-regulation and LATS1 down-regulation were closely associated with tumorigenesis and progression of SCC PMID: 25618271
  24. High ITCH expression enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway PMID: 25350971
  25. these observations reveal that Itch and Yap1 have antagonistic roles in the regulation of ASPP2 protein stability through competing post-translational regulatory mechanism of ASPP2. PMID: 25436413
  26. The C-terminal domain of PTCH1 interacts with and is ubiquitylated on K1413 by the E3 ubiquitin-protein ligase Itchy homolog Itch. PMID: 25092867
  27. ITCH as a novel component of the ATM-dependent signaling pathway. PMID: 23435430
  28. Data indicate that Itch interacted with viral M1 protein and ubiquitinated M1 protein. PMID: 24101521
  29. identify Itch as a regulator of Oct4 stability and transcriptional activity, establishing a functional link between an E3 ligase and the regulation of pluripotency PMID: 23255053
  30. ITCH interacts with mutant GCase variants and mediates their lysine 48 polyubiquitination and degradation. PMID: 23255161
  31. Amot130 repurposes AIP4 from its previously described role in degrading large tumor suppressor 1 to the inhibition of YAP and cell growth. PMID: 23564455
  32. FOXP3 mRNA expression correlated with CBLB and ITCH in MS patients. PMID: 23039885
  33. The interaction of Itch-WW2 domain with p63, was investigated. PMID: 22935697
  34. Overexpression of ITCH inhibited wild-type DVL2 -induced, but not DVL2-Y568F mutant-induced, Wnt reporter activity. PMID: 22826439
  35. JNK1-dependent increase in labile iron pool is mediated by Itch ubiquitin ligase. PMID: 21863240
  36. Knockdown of Nedd4, Nedd4-2 and Itch causes an accumulation of steady-state level of AMOT/p130. PMID: 22385262
  37. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL-induced apoptosis. PMID: 21107885
  38. Overexpression of an AIP4 catalytically inactive mutant and a mutant that shows poor binding to STAM-1 fails to enhance CXCR4-induced ERK-1/2 signaling. PMID: 22275353
  39. LAPTM5 is a substrate of the ITCH-mediated degradation and its protein level is negatively regulated by ITCH PMID: 22009753
  40. Only silencing of ITCH, but not of WWP1, WWP2, and Nedd4, resulted in a reduction of HTLV-1 budding from 293T cells PMID: 21724848
  41. Itch protein re-localization is dependent upon the interaction with the PPXY sequences of LITAF, since disruption of these binding motifs completely abrogates Itch re-localization. PMID: 21326863
  42. study identifies E3 ubiquitin ligase Itch as a unique negative regulator of LATS1 and presents a possibility of targeting LATS1/Itch interaction as a therapeutic strategy in cancer. PMID: 21383157
  43. Findings support a role for the AKT-dependent regulation of AIP4/Itch activity in mediating the differential cyclin D1 and c-MYC transcriptional responses to rapamycin. PMID: 21135252
  44. ubiquitin E3 ligase ITCH physically and functionally associates with LATS1 PMID: 21212414
  45. Numb activates the catalytic activity of Itch, releasing it from an inhibitory intramolecular interaction between its homologous to E6-AP C-terminus and WW domains. PMID: 20818436
  46. MDM2 promotes Itch-mediated degradation of p73 through the interaction with Itch in HeLa cells. PMID: 21093410
  47. UL56 interacted with Itch, independent of additional viral proteins, and mediated more striking degradation of Itch, compared to Nedd4. PMID: 20682038
  48. Results indicate that cystatin B regulates Itch-mediated degradation of FLIP(L) and thereby TRAIL-induced apoptosis in melanoma cells. PMID: 20300110
  49. Itch ubiquitylates SNX9 and regulates intracellular SNX9 levels. Interaction with the proline-rich domain of Itch is essential for SNX9 ubiquitylation and degradation. PMID: 20491914
  50. Inducible regulatory T cells (iTregs) from recent onset type 1 diabetes (RO T1D) subjects had increased expression of Foxp3, E3 ubiquitin ligase (ITCH) and TGF-beta-inducible early gene 1 (TIEG1) compared with control and long-standing T1D subjects. PMID: 20143240

Show More

Hide All

Database Links

HGNC: 13890

OMIM: 606409

KEGG: hsa:83737

STRING: 9606.ENSP00000363998

UniGene: Hs.632272

Involvement In Disease
Autoimmune disease, multisystem, with facial dysmorphism (ADMFD)
Subcellular Location
Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm. Nucleus. Early endosome membrane; Peripheral membrane protein; Cytoplasmic side. Endosome membrane; Peripheral membrane protein; Cytoplasmic side.
Tissue Specificity
Widely expressed.

Q&A

What is ITCH (Ab-420) Antibody and what epitope does it recognize?

ITCH (Ab-420) Antibody is a rabbit polyclonal antibody that detects endogenous levels of total ITCH protein, a critical E3 ubiquitin-protein ligase in cellular signaling pathways. This antibody specifically recognizes the region surrounding the tyrosine 420 phosphorylation site (F-I-Y(p)-G-N) within human ITCH protein . The immunogen used to generate this antibody is a synthesized non-phosphopeptide derived from this specific region, enabling detection of the ITCH protein regardless of its phosphorylation status at this site . The antibody demonstrates reactivity to both human and mouse ITCH proteins, making it suitable for comparative studies across these species .

What are the validated applications for ITCH (Ab-420) Antibody?

Based on empirical validation data, ITCH (Ab-420) Antibody has been confirmed effective for the following applications:

  • Western Blot (WB): Recommended dilutions range from 1:500-1:3000

  • ELISA: Recommended dilutions range from 1:2000-1:10000

The antibody has been validated in Western blot analysis of extracts from mouse brain cells as well as HepG2 human liver cancer cell lines, demonstrating reliable detection of the target protein in diverse tissue and cell types . It's important to note that each new experimental system may require optimization of antibody concentration and assay conditions for optimal results.

What storage conditions maintain ITCH (Ab-420) Antibody stability?

For unconjugated ITCH (Ab-420) Antibody, optimal storage is at -20°C in its formulation buffer consisting of rabbit IgG in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, containing 150mM NaCl, 0.02% sodium azide and 50% glycerol . This formulation provides stability while preventing microbial contamination and freeze-thaw damage.

For conjugated versions of the antibody, storage recommendations vary by conjugate type. Fluorophore-conjugated antibodies (such as AF350, AF488, AF555) should generally be stored at 4°C in the dark for up to 6 months to prevent photobleaching and maintain signal intensity . Always refer to specific product documentation for conjugate-specific storage guidance.

How should ITCH (Ab-420) Antibody be validated for experimental specificity?

A multi-faceted validation approach is recommended:

  • Peptide competition assay: As demonstrated in validation data, pre-incubating the antibody with the synthesized peptide immunogen effectively blocks specific binding in Western blot analysis of HepG2 cells . This approach confirms epitope-specific binding.

  • Positive and negative control samples: Include known ITCH-expressing tissues (such as mouse brain) as positive controls and consider ITCH-knockout or knockdown samples as negative controls when available.

  • Size verification: The ITCH protein has a calculated molecular weight of approximately 103 kDa . Verify that the detected band appears at the expected molecular weight.

  • Cross-species comparison: The validated reactivity to both human and mouse samples provides an opportunity for specificity verification across species with conserved epitopes.

What are the optimal conditions for using ITCH (Ab-420) Antibody in complex tissue samples?

When working with complex tissue samples such as brain tissue:

  • Sample preparation optimization: Thoroughly homogenize tissues in appropriate lysis buffers containing protease and phosphatase inhibitors to prevent degradation.

  • Blocking optimization: Use 5% non-fat dry milk or BSA in TBST for Western blot applications to minimize background signal.

  • Antibody dilution titration: Begin with the manufacturer's recommended range (1:500-1:3000 for WB) but perform a dilution series to determine optimal signal-to-noise ratio for your specific sample type.

  • Incubation conditions: For brain tissue samples, overnight primary antibody incubation at 4°C often yields better results than shorter incubations at room temperature.

  • Detection system selection: Choose detection systems compatible with the expected abundance of ITCH in your samples. Enhanced chemiluminescence (ECL) systems work well for moderate abundance proteins, while more sensitive detection methods may be required for low-abundance samples.

What considerations apply when using conjugated versions of ITCH (Ab-420) Antibody?

ITCH (Ab-420) Antibody is available in multiple conjugated forms with distinct spectral properties to support various experimental platforms:

Conjugate TypeExcitation (nm)Emission (nm)Recommended Applications
AF350346442Flow cytometry, microscopy with UV excitation
AF488493519Flow cytometry, standard fluorescence microscopy
AF555555565Multiplex imaging with green fluorophores
AF594591614Confocal microscopy
AF647651667Flow cytometry, far-red imaging
AF680679702Near-infrared imaging systems
AF750749775In vivo imaging applications

When using conjugated antibodies:

  • Protect from light during all handling steps

  • Consider spectral overlap when designing multiplex experiments

  • Include appropriate single-stained controls for compensation in flow cytometry

  • Titrate antibody concentration for optimal signal-to-noise ratio

How can non-specific binding be reduced when using ITCH (Ab-420) Antibody?

If experiencing non-specific binding or high background:

  • Increase blocking stringency: Extend blocking time to 2 hours or switch blocking reagent (BSA vs. milk) based on your detection system.

  • Optimize antibody concentration: Further dilute the antibody beyond the recommended range if signal-to-noise ratio is poor.

  • Add detergent: Increase Tween-20 concentration in wash buffers to 0.1-0.3% to reduce hydrophobic interactions.

  • Pre-absorb the antibody: For tissues with known cross-reactivity issues, consider pre-absorbing the antibody with tissue lysate from a negative control sample.

  • Peptide competition: Use the immunizing peptide as a competitive inhibitor to distinguish between specific and non-specific binding.

What are the key considerations for quantitative analysis of ITCH expression using this antibody?

For reliable quantitative analysis:

  • Loading control selection: Choose appropriate loading controls based on your experimental system (β-actin, GAPDH, or total protein staining).

  • Linear dynamic range determination: Perform a sample dilution series to ensure quantification occurs within the linear detection range of both the antibody and detection system.

  • Normalization strategy: For phosphorylation studies, normalize phospho-specific signals to total ITCH protein levels rather than just to loading controls.

  • Technical replicates: Include at least three technical replicates for statistical validity.

  • Image acquisition parameters: Use identical exposure settings when comparing samples across different blots or immunofluorescence images.

How can ITCH (Ab-420) Antibody be applied to study ITCH's role in protein ubiquitination?

ITCH functions as an E3 ubiquitin ligase involved in protein degradation pathways. To study this function:

  • Co-immunoprecipitation studies: Use ITCH (Ab-420) Antibody to pull down ITCH complexes and analyze associated proteins to identify novel substrates.

  • Ubiquitination assays: Combine with anti-ubiquitin antibodies in Western blot analyses to detect ubiquitinated substrates after ITCH immunoprecipitation.

  • Inhibitor studies: Examine changes in ITCH-substrate interactions following treatment with proteasome inhibitors (MG132) or deubiquitinase inhibitors.

  • Phosphorylation impact: Since the antibody targets a region near Tyr420, it can be used alongside phospho-specific antibodies to determine how phosphorylation affects ITCH's ubiquitin ligase activity.

  • Degradation kinetics: Track substrate protein levels over time following ITCH activation or inhibition to characterize degradation kinetics.

What approaches are recommended for studying ITCH protein interactions with its known binding partners?

To investigate protein-protein interactions:

  • Proximity ligation assay (PLA): Combine ITCH (Ab-420) Antibody with antibodies against suspected binding partners to visualize and quantify interactions in situ.

  • FRET analysis: Use fluorophore-conjugated versions of ITCH (Ab-420) Antibody in combination with differently-labeled partner antibodies to study interaction dynamics in living cells.

  • Pull-down confirmation: Follow up on observed interactions with reciprocal immunoprecipitation using both ITCH (Ab-420) Antibody and antibodies against binding partners.

  • Domain mapping: Combine with deletion mutant studies to identify specific interaction domains.

  • Stimulus-response experiments: Monitor how interactions change in response to cellular stressors, signaling activators, or inhibitors.

How does ITCH (Ab-420) Antibody compare to antibodies targeting other epitopes of ITCH protein?

When selecting between different ITCH antibodies:

  • Epitope accessibility: The Ab-420 antibody targets a region around tyrosine 420, which may have different accessibility depending on protein conformation and interaction partners compared to antibodies targeting N-terminal or C-terminal epitopes.

  • Post-translational modification sensitivity: Unlike phospho-specific antibodies, ITCH (Ab-420) Antibody detects total ITCH protein regardless of phosphorylation status, making it suitable for normalization in phosphorylation studies.

  • Cross-reactivity profile: The specificity for human and mouse ITCH proteins makes this antibody suitable for comparative studies across these species, but researchers working with other model organisms should verify cross-reactivity.

  • Application versatility: The validated applications (WB, ELISA) may differ from other epitope-targeting antibodies that might be validated for additional applications like immunohistochemistry or immunofluorescence.

  • Isoform detection: Consider whether the targeted epitope is present in all known ITCH isoforms relevant to your research question.

What experimental controls should be included when using ITCH (Ab-420) Antibody in new research contexts?

For robust experimental design:

  • Technical validation controls:

    • Primary antibody omission control

    • Isotype control (rabbit IgG at equivalent concentration)

    • Peptide competition control using the immunizing peptide

  • Biological controls:

    • Positive control tissues/cells with known ITCH expression (mouse brain, HepG2 cells)

    • ITCH knockdown/knockout validation where available

    • Cross-species comparison when studying conserved mechanisms

  • Quantification controls:

    • Standard curve for quantitative applications

    • Loading controls appropriate to your experimental system

    • Replicate samples for statistical analysis

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.